Monthly Archives: February 2018

Acute pancreatitis (AP) was the third most common gastrointestinal diagnosis in 2012, resulting in approximately 275,000 admissions and costing about $2.6 billion.1,2 It is also the most common pancreatic disease worldwide.3 The incidence is increasing, but death rates have actually decreased in recent years to <2%.1 However, ≥50% of the deaths occur within the first 2 weeks of diagnosis.4,5 The recent revised Atlanta classification6 described mild (usually interstitial), moderately severe (local complications without persistent organ failure), and severe (persistent organ failure) AP subtypes. Continue reading →

This document presents the official recommendations of the American Gastroenterological Association (AGA) on the initial management of acute pancreatitis (AP). The guideline was developed by the AGA’s Clinical Practice Guideline Committee and approve… Continue reading →

We investigated whether intra-pancreatic coagulation, with deposition of the fibrinogen-γ dimer (Fib-γD) and hypoxia, affect the severity of acute pancreatitis (AP) in mice. Pancreata of mice with AP induced by administration of cerulein or by L-argi… Continue reading →

Ceramide, a sphingolipid metabolite, affects T-cell signaling, induces apoptosis of cancer cells, and slows tumor growth in mice. However, it has not been used as a chemotherapeutic agent because of its cell impermeability and precipitation in aqueous … Continue reading →